Abstract
The mitogen-activated protein kinase (MEK) inhibitor selumetinib was shown in a prior industry-funded, multicenter, randomized, phase II study to have clinical efficacy in KRAS -mutant advanced non–small-cell lung cancer (NSCLC) when combined with docetaxel (Lancet Oncol 2013;14:38). To further examine this finding, investigators have conducted a similar phase III trial (SELECT-1), in which 505 previously treated KRAS -mutated NSCLC patients received docetaxel with or without selumetinib. Results were as follows:
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
